Contrasting Neurogene (NGNE) & Its Rivals

Neurogene (NASDAQ:NGNE) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Neurogene to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, profitability, valuation and earnings.

Profitability

This table compares Neurogene and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Neurogene Competitors	-12,357.18%	-197.96%	-30.56%

Analyst Recommendations

This is a summary of current recommendations and price targets for Neurogene and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1	0	5	2	3.00
Neurogene Competitors	9834	15121	45433	1587	2.54

Neurogene presently has a consensus price target of $80.29, indicating a potential upside of 217.21%. As a group, “Biotechnology” companies have a potential upside of 102.43%. Given Neurogene’s stronger consensus rating and higher possible upside, equities analysts clearly believe Neurogene is more favorable than its rivals.

Volatility & Risk

Neurogene has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Neurogene’s rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Institutional and Insider Ownership

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Neurogene and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neurogene	$930,000.00	-$90.35 million	-5.03
Neurogene Competitors	$719.50 million	$12.16 million	-15.19

Neurogene’s rivals have higher revenue and earnings than Neurogene. Neurogene is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Neurogene beats its rivals on 8 of the 13 factors compared.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.